Limits...
Ziprasidone in the treatment of mania in bipolar disorder.

Nicolson SE, Nemeroff CB - Neuropsychiatr Dis Treat (2007)

Bottom Line: When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation.However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied.Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

ABSTRACT
Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.

No MeSH data available.


Related in: MedlinePlus

Decrease in MRS psychotic mania vs non-psychotic mania after 21 days (estimated from Potkin et al 2004).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2656324&req=5

f2-ndt-3-823: Decrease in MRS psychotic mania vs non-psychotic mania after 21 days (estimated from Potkin et al 2004).

Mentions: In the pooled analysis discussed above, patients with psychotic symptoms who were in the ziprasidone treatment group (n = 116) had nearly double the magnitude of decrease in their MRS scores by endpoint when compared to psychotic patients who received placebo (n = 52) (see Figure 2). This difference was statistically significant at day 4 (p < 0.01) and was maintained to endpoint (Potkin et al 2004).


Ziprasidone in the treatment of mania in bipolar disorder.

Nicolson SE, Nemeroff CB - Neuropsychiatr Dis Treat (2007)

Decrease in MRS psychotic mania vs non-psychotic mania after 21 days (estimated from Potkin et al 2004).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2656324&req=5

f2-ndt-3-823: Decrease in MRS psychotic mania vs non-psychotic mania after 21 days (estimated from Potkin et al 2004).
Mentions: In the pooled analysis discussed above, patients with psychotic symptoms who were in the ziprasidone treatment group (n = 116) had nearly double the magnitude of decrease in their MRS scores by endpoint when compared to psychotic patients who received placebo (n = 52) (see Figure 2). This difference was statistically significant at day 4 (p < 0.01) and was maintained to endpoint (Potkin et al 2004).

Bottom Line: When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation.However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied.Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

ABSTRACT
Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.

No MeSH data available.


Related in: MedlinePlus